Accepted for/Published in: JMIR Formative Research
Date Submitted: Nov 17, 2022
Date Accepted: Apr 4, 2023
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Physician Compliance with Computerized Clinical Decision Support System is a Complete Intermediate Factor in the Anemia Management of Patients with End-Stage Kidney Disease on Hemodialysis: A Retrospective Electronic Health Record Observational Study
ABSTRACT
Background:
Clinical decision support systems (CDSS) have been developed to address anemia, significant morbidity, mortality, and cost in patients with end-stage kidney disease (ESKD) undergoing hemodialysis. However, whether physician compliance with CDSS affects treatment response is yet unclarified.
Objective:
This study investigated the physician compliance with CDSS.
Methods:
We extracted the electronic health records of ESKD patients on hemodialysis at the Far Eastern Memorial Hospital Hemodialysis Center from 2016 to 2020 to evaluate CDSS performance using random intercept models.
Results:
We included 717 eligible hemodialysis patients (mean age, 62.9 +/- 11.6 years; male, 59.9%) with 36,091 hemoglobin measurements (average hemoglobin and on-target [Hb 10-12 g/dL] rate was 11.1 +/- 1.4 g/dL and 59.9%, respectively). On-target rate decreased from 61.3% (pre-CDSS) to 56.2% (post-CDSS) owing to a high hemoglobin percentage of >12 g/dL (pre, 21.5%; post, 29.0%). The failure rate (hemoglobin <10 g/dL) decreased from 17.2 (pre-CDSS) to 14.8% (post-CDSS). The average weekly erythropoietin-stimulating agent (ESA) use of 5,848 ± 4,211 units/week did not differ between phases. The overall concordance between CDSS recommendations and physician prescriptions was 62.3%. The CDSS concordance increased from 56.2% to 78.6% between phases. In the adjusted random intercept model, post-CDSS phase compared with pre-CDSS phase showed increased hemoglobin by 0.17 (95% confidence interval [CI] 0.14-.21) g/dL; weekly ESA by 264 (95% CI 158-371) units/week; and 3.4-fold increased concordance rate (95% CI 3.1-3.6) whereas, on-target rate (29% [odds ratio: OR 0.71, 95%CI 0.66-0.75]) and failure rate (16% [OR 0.84, 95%CI 0.76-0.92]) reduced. After additional adjustments for concordance in the full models, increased hemoglobin and decreased on-target rate tended towards attenuation (from 0.17 to 0.13 g/dL and 0.71 to 0.73, respectively). Increased ESA and decreased failure rate were completely mediated by CDSS concordance (from 264 to 50 units and 0.84 to 0.97, respectively).
Conclusions:
CDSS reduced the failure rate of anemia management, and physician compliance with CDSS was a complete intermediate factor accounting for CDSS effects. Further studies are warranted to address factors influencing physician compliance, to improve patient outcomes.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.